可解释人工智能在前列腺癌治疗推荐中的应用:面向肿瘤专家组的决策支持系统
该研究基于2015至2022年多学科癌症会议(MCC)讨论的5478例前列腺癌病例,构建可解释AI系统复现MCC治疗决策。系统采用分层建模框架,先预测治疗大类再细化具体策略,高层分类F1分数手术0.89、放疗0.81,详细推荐前列腺切除术0.99、PSMA配体治疗0.98。特征重要性分析保障模型透明性,结论认为该系统可作为多学科肿瘤学的可扩展决策支持工具,需前瞻性验证。
要点
- 可解释AI系统能高精度复现MCC对前列腺癌的治疗推荐。
- 分层建模先预测治疗大类再细化具体策略,F1分数最高达0.99。
- 特征重要性分析提供模型透明性,支持临床决策支持应用。
核心结论
- 该可解释AI系统能生成与MCC一致的前列腺癌治疗推荐,预测性能强且具可解释性,有潜力作为多学科肿瘤学的可扩展决策支持工具。
研究设计与样本
- 研究纳入2015至2022年MCC讨论的组织学确诊前列腺癌患者临床数据,转换为结构化数据集,共5478例MCC病例、76个临床输入变量和23个治疗输出参数。
- 采用分层建模框架,先预测 overarching 治疗类别再细化治疗策略,训练多种机器学习和深度学习算法复现MCC推荐,以F1分数评估性能。
主要发现
- 高层治疗类别F1分数:手术0.89,放疗0.81。
- 详细推荐F1分数:前列腺切除术0.99,PSMA配体治疗0.98。
- 抗癌药物类别性能较低,可能反映样本量较小。
- 特征重要性分析确保模型透明性和可解释性。
临床怎么用
- 该系统可作为多学科肿瘤学决策支持工具,辅助MCC生成数据驱动的治疗推荐。
- 特征重要性分析可提供模型透明性,增强临床医生对AI推荐的信任。
- 需前瞻性验证后方可临床推广应用。
局限性
- 抗癌药物类别性能较低,可能因样本量较小。
- 研究为回顾性设计,需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic decisions in clinical oncology are commonly established through interdisciplinary consensus in multidisciplinary cancer conferences (MCC). Artificial intelligence (AI) may support these processes by generating data-driven treatment recommendations (TR). We developed and evaluated an explainable AI system designed to reproduce MCC-based treatment decisions for metastatic and non-metastatic prostate cancer (PC). METHODS: Clinical data from patients with histologically confirmed PC discussed in MCC between 2015 and 2022 were transformed into structured datasets. A hierarchical modeling framework was implemented to first predict overarching treatment categories and subsequently specify therapeutic strategies. Multiple machine learning and deep learning algorithms were trained to replicate MCC recommendations. Model performance was assessed using F1-scores. RESULTS: A total of 5478 MCC cases including 76 clinical input variables and 23 treatment output parameters were analyzed. The AI system generated automated TR with high predictive accuracy across both hierarchical levels. For high-level categories, F1-scores reached 0.89 for surgery and 0.81 for radiation therapy. For detailed recommendations, F1-scores reached 0.99 for prostatectomy and 0.98 for PSMA-ligand therapy. Lower performance in anti-cancer drug categories likely reflects smaller sample sizes. Feature importance analyses ensured model transparency and interpretability. CONCLUSION: To our knowledge, this study presents one of the first large-scale explainable AI system capable of generating MCC-aligned treatment recommendations for metastatic and non-metastatic PC within a multi-target framework. It incorporates the largest reported number of clinical input and treatment output parameters in this setting. Strong predictive performance and interpretability support its potential as a scalable decision-support tool in multidisciplinary oncology. Prospective validation is warranted.
引用
- Duwe G, Mercier D, Kauth V, et al. Explainable artificial intelligence in prostate cancer treatment recommendation: A decision support system for oncological expert panels. Eur J Cancer. 2026. PMID: 42235465. doi:10.1016/j.ejca.2026.116849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。